FirstMark, a diagnostic division of GenWay Biotech, has presented the study results for PREvent, a multiple biomarker test that diagnoses near term risk of myocardial infarction for suspected or confirmed coronary artery disease patients.

The PREvent blood test is based on technology developed and patented by GenWay, Emory University and MedStar.

Around 3,000 individuals with suspected or confirmed coronary artery disease were enrolled in Phase I and Phase II trials, in which PREvent identified the top 10% of confirmed coronary artery disease patients, who have a 6.45 times higher risk of a near-term myocardial infarction within a 2-3 year period.

In the study, the test also demonstrated to be 12 times effective than the single biomarker CRP.

GenWay Biotech president and CEO Thomas Silberg said the blood test will allow physicians to identify coronary artery disease patients that are in most urgent need of aggressive treatment and monitoring.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.